<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Epidemiology, clinical manifestations, and diagnosis of brain metastases</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Epidemiology, clinical manifestations, and diagnosis of brain metastases</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Epidemiology, clinical manifestations, and diagnosis of brain metastases</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Helen A Shih, MD, MS, MPH</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Patrick Y Wen, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Glenn A Tung, MD, FACR</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">April F Eichler, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 30, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Brain metastases are the most common intracranial tumors in adults, accounting for significantly more than one-half of brain tumors. In patients with systemic malignancies, brain metastases occur in 10 to 30 percent of adults and 6 to 10 percent of children [<a href="#rid1">1-5</a>].</p><p>The incidence of brain metastases may be increasing, due to both improved detection of small metastases by magnetic resonance imaging (MRI) and better control of extracerebral disease resulting from improved systemic therapy [<a href="#rid4">4-10</a>].</p><p>The etiology, clinical manifestations, and diagnosis of brain metastases will be reviewed here, along with an overview of the approach to treatment. Specific treatment approaches, as well as the use of systemic therapy according to the underlying cancer type, are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5212.html" rel="external">"Overview of the treatment of brain metastases"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/114697.html" rel="external">"Brain metastases in non-small cell lung cancer"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/775.html" rel="external">"Brain metastases in breast cancer"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7611.html" rel="external">"Management of brain metastases in melanoma"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">PRIMARY TUMORS</span><span class="headingEndMark"> — </span>In adults, the most common primary tumors responsible for brain metastases are carcinomas, and include lung, breast, kidney, and colorectal cancers, and melanoma. By contrast, carcinomas of the prostate, esophagus, and oropharynx and non-melanoma skin cancers rarely metastasize to the brain. In children, the most common sources of brain metastases are sarcomas, neuroblastoma, and germ cell tumors [<a href="#rid3">3,9,10</a>].</p><p>For all types of cancer, brain metastases diagnosed during life are relatively uncommon. This was illustrated in two large series, one from the Metropolitan Detroit Cancer Surveillance System and the other from a Dutch series [<a href="#rid11">11,12</a>]. In both studies, the cumulative incidence of brain metastases detected was similar:</p><p class="bulletIndent1"><span class="glyph">●</span>Lung – 16 to 20 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Melanoma – 7 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Renal cell cancer – 7 to 10 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Breast cancer – 5 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Colorectal cancer – 1 to 2 percent</p><p></p><p>In autopsy series, the reported incidence of brain metastases varies widely but is generally substantially higher than that diagnosed antemortem. This is illustrated by a review that found that brain metastases occur in as many as 64 percent of patients dying from lung cancer and 21 percent of those dying from breast cancer [<a href="#rid13">13</a>].</p><p class="headingAnchor" id="H3"><span class="h2">Increasing incidence with advances in systemic therapy</span><span class="headingEndMark"> — </span>Increases in the incidence of brain metastasis have been reported in several solid tumors, thought to be related, at least in part, to advances in the efficacy of systemic therapy:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Breast cancer</strong> – Among women with breast cancer, the incidence of brain metastasis may be increasing and is particularly high in those with lung metastases and those with highly proliferative, hormone receptor-negative tumors, such as triple-negative breast cancer, and those that are also positive for human epidermal growth factor receptor 2 (HER2) overexpression [<a href="#rid14">14-19</a>]. In one series, 15 of 50 patients (30 percent) presenting with lung metastases as the first site of relapse subsequently developed brain metastases during follow-up [<a href="#rid14">14</a>].</p><p></p><p class="bulletIndent1">Although tumor biology might also be at least partly responsible (ie, HER2-positive breast cancers have a higher propensity for metastases to sites such as lung and brain), it is also postulated that the lack of <a class="drug drug_general" data-topicid="10101" href="/d/drug information/10101.html" rel="external">trastuzumab</a> penetration into the central nervous system (CNS), owing to its high molecular weight, coupled with prolonged control of what was previously rapidly lethal systemic disease, leads to "unmasking" of brain metastases that would otherwise have remained clinically silent. (See  <a class="medical medical_review" href="/d/html/775.html" rel="external">"Brain metastases in breast cancer"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Colorectal cancer</strong> – The increasing incidence of brain metastases in patients with metastatic colorectal cancer has been attributed to the longer survival seen with newer systemic therapies [<a href="#rid9">9,20-22</a>]. Compared with the era when <a class="drug drug_general" data-topicid="8464" href="/d/drug information/8464.html" rel="external">fluorouracil</a> was the sole available agent for metastatic disease, median survival has increased markedly with the introduction of <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a>, <a class="drug drug_general" data-topicid="8573" href="/d/drug information/8573.html" rel="external">irinotecan</a>, and biologics (from 6 to 7 to beyond 24 months in selected patients). (See  <a class="medical medical_review" href="/d/html/2503.html" rel="external">"Systemic therapy for nonoperable metastatic colorectal cancer: Selecting the initial therapeutic approach", section on 'Overview of the therapeutic approach'</a>.) </p><p></p><p class="bulletIndent1">However, the incidence of brain metastases in metastatic colorectal cancer is still low, 2.3 percent in one series [<a href="#rid23">23</a>]. Brain metastases are usually a late-stage phenomenon, and the vast majority of patients have metastases in other sites, particularly lung. Outcomes are poor, despite aggressive treatment [<a href="#rid24">24-26</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Non-small cell lung cancer (NSCLC)</strong> – The overall incidence of brain metastases in patients with NSCLC is approximately 16 to 20 percent. However, certain molecular subtypes have an increased propensity for brain metastases, including those with an epidermal growth factor receptor (<em>EGFR</em>) mutation, anaplastic lymphoma kinase (<em>ALK</em>) rearrangement, or <em>HER2</em> mutation. (See  <a class="medical medical_review" href="/d/html/114697.html" rel="external">"Brain metastases in non-small cell lung cancer"</a>.)</p><p></p><p class="headingAnchor" id="H4"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>The most common mechanism of metastasis to the brain is by hematogenous spread [<a href="#rid21">21</a>]. Metastases are usually located directly at the junction of the gray matter and white matter where blood vessels decrease in diameter and act as a trap for clumps of tumor cells [<a href="#rid27">27</a>]. Brain metastases also tend to be more common at the terminal "watershed areas" of arterial circulation. The distribution of metastases roughly follows the relative weight and blood flow in each area [<a href="#rid27">27</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Cerebral hemispheres – approximately 80 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Cerebellum – 15 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Brainstem – 5 percent</p><p></p><p>Different primary tumors may have a predilection for metastasis to different areas within the brain. For example, pelvic (prostatic and uterine), gastrointestinal, and breast tumors more commonly metastasize to the posterior fossa  (<a class="graphic graphic_diagnosticimage graphicRef139746" href="/d/graphic/139746.html" rel="external">image 1</a>) [<a href="#rid27">27,28</a>], while metastases of small cell carcinoma of the lung are equally distributed in all regions of the brain. The reasons for these differences are unclear but may be due to cell surface properties of the metastatic cells and the endothelium within the central nervous system (CNS) vasculature.</p><p class="headingAnchor" id="H5"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>Brain metastases have highly variable clinical features and should be suspected in any cancer patient who develops neurologic symptoms or behavioral abnormalities. However, multiple other causes can also be responsible. In an analysis of over 800 cancer patients evaluated for neurologic symptoms, only 16 percent had brain metastases [<a href="#rid29">29</a>].</p><p>In the majority of patients, a gradually expanding tumor mass and its associated edema cause symptoms. Less commonly, intratumoral hemorrhage, obstructive hydrocephalus, or embolization by tumor cells result in symptoms.</p><p class="headingAnchor" id="H6"><span class="h2">Headache</span><span class="headingEndMark"> — </span>Headaches occur in approximately 40 to 50 percent of patients with brain metastases. The frequency is higher when multiple lesions are present or a metastasis is located in the posterior fossa. Although the classic early morning headache is uncommon, it is highly suggestive when present.</p><p>These general features were illustrated in a review of 111 consecutive patients with primary or metastatic brain tumors identified by computed tomography (CT) or MRI [<a href="#rid30">30</a>]. Headache was present in 48 percent and equally affected those with primary and metastatic tumors. The headaches were similar to tension type in 77 percent, migraine in 9 percent, and other types in 14 percent. The typical headache was bifrontal but worse ipsilaterally; it was the worst symptom in approximately one-half of patients. In contrast to tension-type headaches, brain tumor headaches were worse with bending over in 32 percent, and nausea or vomiting was present in 40 percent. Worsening headache may also follow maneuvers that raise intrathoracic pressure, such as coughing, sneezing, or the Valsalva maneuver. The "classic" early morning brain tumor headache was uncommon.</p><p>Features suggestive of a possible brain tumor in the patient complaining of headaches include nausea and vomiting, a change in prior headache pattern, an abnormal neurologic examination, and positional worsening. (See  <a class="medical medical_review" href="/d/html/14113.html" rel="external">"Brain tumor headache"</a>.)</p><p class="headingAnchor" id="H7"><span class="h2">Focal neurologic dysfunction</span><span class="headingEndMark"> — </span>Focal neurologic dysfunction is the presenting symptom of 20 to 40 percent of patients. Hemiparesis is the most common complaint, but the manifestations depend upon the location of the metastases.</p><p class="headingAnchor" id="H8"><span class="h2">Cognitive dysfunction</span><span class="headingEndMark"> — </span>Cognitive dysfunction, including memory problems and mood or personality changes, is the presenting problem in 30 to 35 percent of patients. However, metabolic encephalopathy is a much more common cause of cognitive dysfunction than metastatic disease in cancer patients who develop an altered mental status [<a href="#rid29">29</a>].</p><p class="headingAnchor" id="H9"><span class="h2">Seizures</span><span class="headingEndMark"> — </span>New onset of seizures is the presenting symptom in 10 to 20 percent of patients [<a href="#rid31">31-34</a>]. Seizures in patients with brain metastases are almost exclusively associated with supratentorial disease [<a href="#rid32">32</a>].</p><p class="headingAnchor" id="H10"><span class="h2">Stroke</span><span class="headingEndMark"> — </span>Another 5 to 10 percent present acutely due to stroke caused by hemorrhage into a metastasis, hypercoagulability, invasion or compression of an artery by tumor, or embolization of tumor cells [<a href="#rid7">7,35</a>]. Melanoma, choriocarcinoma, and thyroid and renal carcinoma have a particular propensity to bleed  (<a class="graphic graphic_diagnosticimage graphicRef139747" href="/d/graphic/139747.html" rel="external">image 2</a>) [<a href="#rid7">7</a>].</p><p class="headingAnchor" id="H11"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>Brain metastases must be distinguished from primary brain tumors, infectious processes, progressive multifocal leukoencephalopathy, demyelination, paraneoplastic phenomena, cerebral infarction or bleeding, and effects of treatment such as radiation necrosis. (See  <a class="medical medical_review" href="/d/html/5180.html" rel="external">"Overview of the clinical features and diagnosis of brain tumors in adults", section on 'Differential diagnosis'</a>.)</p><p>Imaging studies provide useful information, but brain biopsy is necessary in some cases for a definitive diagnosis. Other important diagnostic issues include determining the number and location of metastases and the evaluation of the patient without a known primary tumor.</p><p class="headingAnchor" id="H12"><span class="h2">Imaging studies</span><span class="headingEndMark"> — </span>Contrast-enhanced MRI is the preferred imaging study for the diagnosis of brain metastases [<a href="#rid36">36-39</a>]. Contrast-enhanced MRI is more sensitive than either nonenhanced MRI or CT scanning in detecting lesions in patients suspected of having cerebral metastases and in differentiating metastases from other central nervous system (CNS) lesions [<a href="#rid37">37,38</a>]. CT may highlight calcifications associated with brain metastases, especially in patients with non-small cell lung cancer (NSCLC) [<a href="#rid40">40</a>].</p><p>Brain metastases are most commonly discrete, circumscribed masses that enhance after contrast administration  (<a class="graphic graphic_diagnosticimage graphicRef139746" href="/d/graphic/139746.html" rel="external">image 1</a> and <a class="graphic graphic_diagnosticimage graphicRef139748" href="/d/graphic/139748.html" rel="external">image 3</a> and <a class="graphic graphic_diagnosticimage graphicRef139749" href="/d/graphic/139749.html" rel="external">image 4</a> and <a class="graphic graphic_diagnosticimage graphicRef139750" href="/d/graphic/139750.html" rel="external">image 5</a>). Some metastases are cystic or have both cystic and solid components  (<a class="graphic graphic_diagnosticimage graphicRef139748" href="/d/graphic/139748.html" rel="external">image 3</a>). Other imaging features that can help differentiate brain metastases from other CNS lesions include the following [<a href="#rid6">6</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>The presence of multiple lesions  (<a class="graphic graphic_diagnosticimage graphicRef139748" href="/d/graphic/139748.html" rel="external">image 3</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Localization at the junction of the gray and white matter  (<a class="graphic graphic_diagnosticimage graphicRef139748" href="/d/graphic/139748.html" rel="external">image 3</a> and <a class="graphic graphic_diagnosticimage graphicRef139749" href="/d/graphic/139749.html" rel="external">image 4</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Circumscribed margins, in contrast to high-grade glioma, which has infiltrative margins  (<a class="graphic graphic_diagnosticimage graphicRef139746" href="/d/graphic/139746.html" rel="external">image 1</a> and <a class="graphic graphic_diagnosticimage graphicRef139747" href="/d/graphic/139747.html" rel="external">image 2</a> and <a class="graphic graphic_diagnosticimage graphicRef139748" href="/d/graphic/139748.html" rel="external">image 3</a> and <a class="graphic graphic_diagnosticimage graphicRef139749" href="/d/graphic/139749.html" rel="external">image 4</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Large volume of associated vasogenic edema compared with the size of the lesion  (<a class="graphic graphic_diagnosticimage graphicRef139749" href="/d/graphic/139749.html" rel="external">image 4</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Absence of marked reduced diffusivity, particularly in the center or core of the lesion; reduced water diffusion in the center of a mass is more typical of pyogenic brain abscess</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Almost all brain metastases enhance, but the pattern of enhancement is variable  (<a class="graphic graphic_diagnosticimage graphicRef139746" href="/d/graphic/139746.html" rel="external">image 1</a> and <a class="graphic graphic_diagnosticimage graphicRef139748" href="/d/graphic/139748.html" rel="external">image 3</a> and <a class="graphic graphic_diagnosticimage graphicRef139749" href="/d/graphic/139749.html" rel="external">image 4</a> and <a class="graphic graphic_diagnosticimage graphicRef139750" href="/d/graphic/139750.html" rel="external">image 5</a>)</p><p></p><p>Perfusion-weighted imaging is an MRI method that measures cerebral blood flow and volume after the administration of intravenous contrast. As such, it enables study of tissue perfusion at the capillary level and has been used to characterize brain tumors [<a href="#rid41">41</a>]. Studies have shown that the percentage of signal recovery, obtained from the time-signal curve, can be used to differentiate metastasis from high-grade glioma and primary CNS lymphoma [<a href="#rid42">42-44</a>].</p><p class="headingAnchor" id="H13"><span class="h2">Biopsy</span><span class="headingEndMark"> — </span>Biopsy should be performed when the diagnosis of brain metastases is in doubt. Biopsy material is most commonly obtained at the time of a resection. This is particularly important in patients with a single lesion. The importance of biopsy was demonstrated in a study in which the diagnosis of metastasis was changed by biopsy in 6 of 54 patients with a single lesion [<a href="#rid45">45</a>]. These six patients had primary brain tumors, infections, or inflammatory processes.</p><p>Breast cancer patients with a single dural-based lesion pose a particular diagnostic dilemma, since the incidence of meningiomas is increased in these patients [<a href="#rid46">46,47</a>]. Imaging studies are often inconclusive, but the presence of edema in the underlying brain and an irregular margin of the lesion may suggest a dural metastasis instead of a meningioma  (<a class="graphic graphic_diagnosticimage graphicRef139750" href="/d/graphic/139750.html" rel="external">image 5</a>). However, biopsy or surgical resection of the lesion may be required to establish the diagnosis. (See  <a class="medical medical_review" href="/d/html/5220.html" rel="external">"Epidemiology, pathology, clinical features, and diagnosis of meningioma", section on 'Diagnostic evaluation'</a>.)</p><p class="headingAnchor" id="H14"><span class="h2">Unknown primary tumor</span><span class="headingEndMark"> — </span>In approximately 80 percent of patients, brain metastases develop after the diagnosis of systemic cancer (metachronous presentation) [<a href="#rid1">1</a>]. In the remaining patients, brain metastases become evident either at the same time (synchronous presentation) or before the primary tumor is found (precocious presentation). In these situations, histopathology of the biopsy specimen, including immunohistochemistry, can often help identify the primary [<a href="#rid48">48</a>]. Lung cancer is the most common cancer type associated with a synchronous presentation of brain and systemic disease [<a href="#rid49">49,50</a>]. </p><p>For patients who present with biopsy-proven brain metastases without a known primary tumor, the lung should be the primary focus of the evaluation. Over 60 percent of such patients have a primary lung cancer or pulmonary metastases from a primary tumor located elsewhere [<a href="#rid51">51-54</a>]. Other relatively frequent sites include melanoma and colon cancer, while the primary remains unknown in approximately 25 to 30 percent of cases. (See  <a class="medical medical_review" href="/d/html/4878.html" rel="external">"Overview of the classification and management of cancers of unknown primary site"</a>.)</p><p>The history and physical examination demonstrate the site of origin in one-quarter to one-third of patients. Chest CT scan should be performed since this significantly increases the likelihood of detecting a lung cancer. This was illustrated in a report of 31 patients who presented with brain metastases without a known primary and subsequently were determined to have primary lung cancer by CT scan; chest radiographs were positive in only 19 (59 percent) [<a href="#rid51">51</a>]. These patients should also have a CT scan of the abdomen and pelvis and a bone scan to determine the extent of metastatic disease.</p><p>Positron emission tomography (PET) may also be useful in these patients, either by identifying the primary tumor or by finding other sites of metastatic disease that can be biopsied more readily.</p><p class="headingAnchor" id="H15"><span class="h2">Number of metastases</span><span class="headingEndMark"> — </span>Patients with a single or limited number of small metastases should be differentiated from those with more extensive involvement since treatment may be different. Although earlier studies based upon CT scans suggested that as many as 50 percent of patients had a single metastasis, MRI suggests that the true frequency of single metastases is lower, accounting for only one-fourth to one-third of patients with cerebral metastases [<a href="#rid6">6,36,37</a>]. Metastases from breast, colon, and renal cell carcinoma are more often single, while lung cancer and malignant melanoma have a greater tendency to produce multiple metastases [<a href="#rid27">27</a>].</p><p class="headingAnchor" id="H624623706"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/15364.html" rel="external">"Patient education: Brain cancer (The Basics)"</a> and  <a class="medical medical_basics" href="/d/html/86632.html" rel="external">"Patient education: Brain metastases (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/857.html" rel="external">"Patient education: Low-grade glioma in adults (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/855.html" rel="external">"Patient education: High-grade glioma in adults (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/853.html" rel="external">"Patient education: Meningioma (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H22"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> – Brain metastases are the most common intracranial tumors in adults, occurring in approximately 10 percent of cancer patients at some point during their illness and accounting for significantly more than one-half of all brain tumors. Lung cancer, melanoma, renal cell carcinoma, and breast cancer are the most common primary tumors that metastasize to the brain. (See <a class="local">'Primary tumors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong> – Metastases can cause a variety of symptoms, including headache, focal neurologic deficits, cognitive dysfunction, seizures, and stroke. The development of any neurologic symptom in a patient with cancer requires consideration of the diagnosis of metastasis, although other causes are responsible in the majority of cases. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – Contrast-enhanced MRI is the most reliable imaging procedure to make the diagnosis. Brain metastases are most commonly circumscribed, solid, spherical masses that enhance after contrast administration and often have surrounding edema  (<a class="graphic graphic_diagnosticimage graphicRef139746" href="/d/graphic/139746.html" rel="external">image 1</a> and <a class="graphic graphic_diagnosticimage graphicRef139747" href="/d/graphic/139747.html" rel="external">image 2</a> and <a class="graphic graphic_diagnosticimage graphicRef139749" href="/d/graphic/139749.html" rel="external">image 4</a>). Some metastases are cystic or have a mix of cystic and solid features  (<a class="graphic graphic_diagnosticimage graphicRef139748" href="/d/graphic/139748.html" rel="external">image 3</a>). (See <a class="local">'Imaging studies'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – Brain metastases must be distinguished from primary brain tumors, infectious processes, demyelination, cerebral infarction or bleeding, and effects of treatment such as radiation necrosis. Radiographic features that can help differentiate brain metastases from other central nervous system (CNS) lesions include the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The presence of multiple lesions  (<a class="graphic graphic_diagnosticimage graphicRef139747" href="/d/graphic/139747.html" rel="external">image 2</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Localization at the junction of the gray and white matter  (<a class="graphic graphic_diagnosticimage graphicRef139748" href="/d/graphic/139748.html" rel="external">image 3</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Circumscribed margins  (<a class="graphic graphic_diagnosticimage graphicRef139746" href="/d/graphic/139746.html" rel="external">image 1</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Large amounts of vasogenic edema compared with the size of the lesion  (<a class="graphic graphic_diagnosticimage graphicRef139750" href="/d/graphic/139750.html" rel="external">image 5</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Role of biopsy</strong> – In patients with a single intracranial lesion, biopsy may be required to make a definitive diagnosis, especially when there is minimal or no systemic disease or only a remote history of cancer. In such cases, biopsy material is most commonly obtained at the time of a resection. (See <a class="local">'Biopsy'</a> above and <a class="local">'Unknown primary tumor'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – Patient treatment depends upon the overall prognosis and includes specific measures directed against metastases as well as the prevention and management of complications. (See  <a class="medical medical_review" href="/d/html/5212.html" rel="external">"Overview of the treatment of brain metastases"</a>.)</p><p></p><p class="headingAnchor" id="H42570139"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>We are saddened by the death of Jay S Loeffler, MD, who passed away in June 2023. UpToDate acknowledges Dr. Loeffler's past work as an author for this topic.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Posner JB. Management of brain metastases. Rev Neurol (Paris) 1992; 148:477.</a></li><li class="breakAll">Sawaya R, Bindal RK. Metastatic brain tumors. In: Brain Tumors, Kaye AH, Laws ER (Eds), Churchill Livingstone, Edinburgh 1995. p.923.</li><li><a class="nounderline abstract_t">Graus F, Walker RW, Allen JC. Brain metastases in children. J Pediatr 1983; 103:558.</a></li><li><a class="nounderline abstract_t">Wen PY, Loeffler JS. Management of brain metastases. Oncology (Williston Park) 1999; 13:941.</a></li><li><a class="nounderline abstract_t">Johnson JD, Young B. Demographics of brain metastasis. Neurosurg Clin N Am 1996; 7:337.</a></li><li class="breakAll">Loeffler JS, Patchell RA, Sawaya R. Metastatic brain cancer. In: Cancer: Principles and Practice of Oncology, Davita VT, Hellman S, Rosenberg SA (Eds), JP Lippincott, Philadelphia 1997. p.2523.</li><li class="breakAll">Posner JB. Neurologic Complications of Cancer, FA Davis, 1995.</li><li><a class="nounderline abstract_t">Paterson AH, Agarwal M, Lees A, et al. Brain metastases in breast cancer patients receiving adjuvant chemotherapy. Cancer 1982; 49:651.</a></li><li><a class="nounderline abstract_t">Sundermeyer ML, Meropol NJ, Rogatko A, et al. Changing patterns of bone and brain metastases in patients with colorectal cancer. Clin Colorectal Cancer 2005; 5:108.</a></li><li><a class="nounderline abstract_t">Bouffet E, Doumi N, Thiesse P, et al. Brain metastases in children with solid tumors. Cancer 1997; 79:403.</a></li><li><a class="nounderline abstract_t">Barnholtz-Sloan JS, Sloan AE, Davis FG, et al. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol 2004; 22:2865.</a></li><li><a class="nounderline abstract_t">Schouten LJ, Rutten J, Huveneers HA, Twijnstra A. Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer 2002; 94:2698.</a></li><li><a class="nounderline abstract_t">Lassman AB, DeAngelis LM. Brain metastases. Neurol Clin 2003; 21:1.</a></li><li><a class="nounderline abstract_t">Slimane K, Andre F, Delaloge S, et al. Risk factors for brain relapse in patients with metastatic breast cancer. Ann Oncol 2004; 15:1640.</a></li><li><a class="nounderline abstract_t">Crivellari D, Pagani O, Veronesi A, et al. High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel. Ann Oncol 2001; 12:353.</a></li><li><a class="nounderline abstract_t">Miller KD, Weathers T, Haney LG, et al. Occult central nervous system involvement in patients with metastatic breast cancer: prevalence, predictive factors and impact on overall survival. Ann Oncol 2003; 14:1072.</a></li><li><a class="nounderline abstract_t">Tham YL, Sexton K, Kramer R, et al. Primary breast cancer phenotypes associated with propensity for central nervous system metastases. Cancer 2006; 107:696.</a></li><li><a class="nounderline abstract_t">Lin NU, Winer EP. Brain metastases: the HER2 paradigm. Clin Cancer Res 2007; 13:1648.</a></li><li><a class="nounderline abstract_t">Gori S, Rimondini S, De Angelis V, et al. Central nervous system metastases in HER-2 positive metastatic breast cancer patients treated with trastuzumab: incidence, survival, and risk factors. Oncologist 2007; 12:766.</a></li><li><a class="nounderline abstract_t">Kruser TJ, Chao ST, Elson P, et al. Multidisciplinary management of colorectal brain metastases: a retrospective study. Cancer 2008; 113:158.</a></li><li><a class="nounderline abstract_t">Gavrilovic IT, Posner JB. Brain metastases: epidemiology and pathophysiology. J Neurooncol 2005; 75:5.</a></li><li><a class="nounderline abstract_t">Shindorf ML, Jafferji MS, Goff SL. Incidence of Asymptomatic Brain Metastases in Metastatic Colorectal Cancer. Clin Colorectal Cancer 2020; 19:263.</a></li><li><a class="nounderline abstract_t">Mongan JP, Fadul CE, Cole BF, et al. Brain metastases from colorectal cancer: risk factors, incidence, and the possible role of chemokines. Clin Colorectal Cancer 2009; 8:100.</a></li><li><a class="nounderline abstract_t">Nieder C, Pawinski A, Balteskard L. Colorectal cancer metastatic to the brain: time trends in presentation and outcome. Oncology 2009; 76:369.</a></li><li><a class="nounderline abstract_t">Aprile G, Zanon E, Tuniz F, et al. Neurosurgical management and postoperative whole-brain radiotherapy for colorectal cancer patients with symptomatic brain metastases. J Cancer Res Clin Oncol 2009; 135:451.</a></li><li><a class="nounderline abstract_t">Baek JY, Kang MH, Hong YS, et al. Characteristics and prognosis of patients with colorectal cancer-associated brain metastases in the era of modern systemic chemotherapy. J Neurooncol 2011; 104:745.</a></li><li><a class="nounderline abstract_t">Delattre JY, Krol G, Thaler HT, Posner JB. Distribution of brain metastases. Arch Neurol 1988; 45:741.</a></li><li><a class="nounderline abstract_t">Quattrocchi CC, Errante Y, Gaudino C, et al. Spatial brain distribution of intra-axial metastatic lesions in breast and lung cancer patients. J Neurooncol 2012; 110:79.</a></li><li><a class="nounderline abstract_t">Clouston PD, DeAngelis LM, Posner JB. The spectrum of neurological disease in patients with systemic cancer. Ann Neurol 1992; 31:268.</a></li><li><a class="nounderline abstract_t">Forsyth PA, Posner JB. Headaches in patients with brain tumors: a study of 111 patients. Neurology 1993; 43:1678.</a></li><li><a class="nounderline abstract_t">Coia LR, Aaronson N, Linggood R, et al. A report of the consensus workshop panel on the treatment of brain metastases. Int J Radiat Oncol Biol Phys 1992; 23:223.</a></li><li><a class="nounderline abstract_t">Cohen N, Strauss G, Lew R, et al. Should prophylactic anticonvulsants be administered to patients with newly-diagnosed cerebral metastases? A retrospective analysis. J Clin Oncol 1988; 6:1621.</a></li><li><a class="nounderline abstract_t">Glantz MJ, Cole BF, Friedberg MH, et al. A randomized, blinded, placebo-controlled trial of divalproex sodium prophylaxis in adults with newly diagnosed brain tumors. Neurology 1996; 46:985.</a></li><li><a class="nounderline abstract_t">Forsyth PA, Weaver S, Fulton D, et al. Prophylactic anticonvulsants in patients with brain tumour. Can J Neurol Sci 2003; 30:106.</a></li><li><a class="nounderline abstract_t">Nutt SH, Patchell RA. Intracranial hemorrhage associated with primary and secondary tumors. Neurosurg Clin N Am 1992; 3:591.</a></li><li><a class="nounderline abstract_t">Sze G, Milano E, Johnson C, Heier L. Detection of brain metastases: comparison of contrast-enhanced MR with unenhanced MR and enhanced CT. AJNR Am J Neuroradiol 1990; 11:785.</a></li><li><a class="nounderline abstract_t">Davis PC, Hudgins PA, Peterman SB, Hoffman JC Jr. Diagnosis of cerebral metastases: double-dose delayed CT vs contrast-enhanced MR imaging. AJNR Am J Neuroradiol 1991; 12:293.</a></li><li><a class="nounderline abstract_t">Schaefer PW, Budzik RF Jr, Gonzalez RG. Imaging of cerebral metastases. Neurosurg Clin N Am 1996; 7:393.</a></li><li><a class="nounderline abstract_t">Muroff LR, Runge VM. The use of MR contrast in neoplastic disease of the brain. Top Magn Reson Imaging 1995; 7:137.</a></li><li><a class="nounderline abstract_t">Rebella G, Romano N, Silvestri G, et al. Calcified brain metastases may be more frequent than normally considered. Eur Radiol 2021; 31:650.</a></li><li><a class="nounderline abstract_t">Welker K, Boxerman J, Kalnin A, et al. ASFNR recommendations for clinical performance of MR dynamic susceptibility contrast perfusion imaging of the brain. AJNR Am J Neuroradiol 2015; 36:E41.</a></li><li><a class="nounderline abstract_t">Cha S, Lupo JM, Chen MH, et al. Differentiation of glioblastoma multiforme and single brain metastasis by peak height and percentage of signal intensity recovery derived from dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. AJNR Am J Neuroradiol 2007; 28:1078.</a></li><li><a class="nounderline abstract_t">Mangla R, Kolar B, Zhu T, et al. Percentage signal recovery derived from MR dynamic susceptibility contrast imaging is useful to differentiate common enhancing malignant lesions of the brain. AJNR Am J Neuroradiol 2011; 32:1004.</a></li><li><a class="nounderline abstract_t">Cindil E, Sendur HN, Cerit MN, et al. Validation of combined use of DWI and percentage signal recovery-optimized protocol of DSC-MRI in differentiation of high-grade glioma, metastasis, and lymphoma. Neuroradiology 2021; 63:331.</a></li><li><a class="nounderline abstract_t">Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 1990; 322:494.</a></li><li><a class="nounderline abstract_t">Schoenberg BS, Christine BW, Whisnant JP. Nervous system neoplasms and primary malignancies of other sites. The unique association between meningiomas and breast cancer. Neurology 1975; 25:705.</a></li><li><a class="nounderline abstract_t">Lopez-Rivera V, Zhu P, Dono A, et al. Increased Risk of Subsequent Meningioma Among Women with Malignant Breast Cancer. World Neurosurg 2020; 139:e271.</a></li><li><a class="nounderline abstract_t">Drlicek M, Bodenteich A, Urbanits S, Grisold W. Immunohistochemical panel of antibodies in the diagnosis of brain metastases of the unknown primary. Pathol Res Pract 2004; 200:727.</a></li><li><a class="nounderline abstract_t">Kromer C, Xu J, Ostrom QT, et al. Estimating the annual frequency of synchronous brain metastasis in the United States 2010-2013: a population-based study. J Neurooncol 2017; 134:55.</a></li><li><a class="nounderline abstract_t">Cagney DN, Martin AM, Catalano PJ, et al. Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study. Neuro Oncol 2017; 19:1511.</a></li><li><a class="nounderline abstract_t">Latief KH, White CS, Protopapas Z, et al. Search for a primary lung neoplasm in patients with brain metastasis: is the chest radiograph sufficient? AJR Am J Roentgenol 1997; 168:1339.</a></li><li><a class="nounderline abstract_t">Merchut MP. Brain metastases from undiagnosed systemic neoplasms. Arch Intern Med 1989; 149:1076.</a></li><li><a class="nounderline abstract_t">van de Pol M, van Aalst VC, Wilmink JT, Twijnstra A. Brain metastases from an unknown primary tumour: which diagnostic procedures are indicated? J Neurol Neurosurg Psychiatry 1996; 61:321.</a></li><li><a class="nounderline abstract_t">Mavrakis AN, Halpern EF, Barker FG 2nd, et al. Diagnostic evaluation of patients with a brain mass as the presenting manifestation of cancer. Neurology 2005; 65:908.</a></li></ol></div><div id="topicVersionRevision">Topic 5217 Version 31.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1448668" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Management of brain metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1448668" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Management of brain metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6620015" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Brain metastases in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10442342" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Management of brain metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8823767" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Demographics of brain metastasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8823767" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Demographics of brain metastasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8823767" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Demographics of brain metastasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7055779" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Brain metastases in breast cancer patients receiving adjuvant chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16098251" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Changing patterns of bone and brain metastases in patients with colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9010115" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Brain metastases in children with solid tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15254054" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12173339" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12690643" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Brain metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15520065" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Risk factors for brain relapse in patients with metastatic breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11332148" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12853349" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Occult central nervous system involvement in patients with metastatic breast cancer: prevalence, predictive factors and impact on overall survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16826579" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Primary breast cancer phenotypes associated with propensity for central nervous system metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17363517" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Brain metastases: the HER2 paradigm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17673608" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Central nervous system metastases in HER-2 positive metastatic breast cancer patients treated with trastuzumab: incidence, survival, and risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18459179" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Multidisciplinary management of colorectal brain metastases: a retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16215811" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Brain metastases: epidemiology and pathophysiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33012679" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Incidence of Asymptomatic Brain Metastases in Metastatic Colorectal Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19423503" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Brain metastases from colorectal cancer: risk factors, incidence, and the possible role of chemokines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19321946" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Colorectal cancer metastatic to the brain: time trends in presentation and outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18779977" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Neurosurgical management and postoperative whole-brain radiotherapy for colorectal cancer patients with symptomatic brain metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21336772" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Characteristics and prognosis of patients with colorectal cancer-associated brain metastases in the era of modern systemic chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3390029" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Distribution of brain metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22802020" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Spatial brain distribution of intra-axial metastatic lesions in breast and lung cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1637135" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : The spectrum of neurological disease in patients with systemic cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8414011" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Headaches in patients with brain tumors: a study of 111 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1572820" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : A report of the consensus workshop panel on the treatment of brain metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3171627" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Should prophylactic anticonvulsants be administered to patients with newly-diagnosed cerebral metastases? A retrospective analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8780077" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : A randomized, blinded, placebo-controlled trial of divalproex sodium prophylaxis in adults with newly diagnosed brain tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12774949" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Prophylactic anticonvulsants in patients with brain tumour.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1633482" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Intracranial hemorrhage associated with primary and secondary tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2114769" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Detection of brain metastases: comparison of contrast-enhanced MR with unenhanced MR and enhanced CT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1902031" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Diagnosis of cerebral metastases: double-dose delayed CT vs contrast-enhanced MR imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8823771" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Imaging of cerebral metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7654393" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : The use of MR contrast in neoplastic disease of the brain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32812176" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Calcified brain metastases may be more frequent than normally considered.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25907520" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : ASFNR recommendations for clinical performance of MR dynamic susceptibility contrast perfusion imaging of the brain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17569962" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Differentiation of glioblastoma multiforme and single brain metastasis by peak height and percentage of signal intensity recovery derived from dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21511863" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Percentage signal recovery derived from MR dynamic susceptibility contrast imaging is useful to differentiate common enhancing malignant lesions of the brain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32821962" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Validation of combined use of DWI and percentage signal recovery-optimized protocol of DSC-MRI in differentiation of high-grade glioma, metastasis, and lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2405271" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : A randomized trial of surgery in the treatment of single metastases to the brain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1171403" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Nervous system neoplasms and primary malignancies of other sites. The unique association between meningiomas and breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32298823" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Increased Risk of Subsequent Meningioma Among Women with Malignant Breast Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15648611" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Immunohistochemical panel of antibodies in the diagnosis of brain metastases of the unknown primary.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28567587" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Estimating the annual frequency of synchronous brain metastasis in the United States 2010-2013: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28444227" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9129439" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Search for a primary lung neoplasm in patients with brain metastasis: is the chest radiograph sufficient?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2719501" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Brain metastases from undiagnosed systemic neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8795609" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Brain metastases from an unknown primary tumour: which diagnostic procedures are indicated?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16186533" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Diagnostic evaluation of patients with a brain mass as the presenting manifestation of cancer.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
